GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » 3-Year Revenue Growth Rate

Samsung BioLogics Co (XKRX:207940) 3-Year Revenue Growth Rate : 39.70% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co 3-Year Revenue Growth Rate?

Samsung BioLogics Co's Revenue per Share for the three months ended in Mar. 2025 was ₩18,240.83.

During the past 12 months, Samsung BioLogics Co's average Revenue per Share Growth Rate was 24.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 39.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 44.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 37.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Samsung BioLogics Co was 63.70% per year. The lowest was 4.50% per year. And the median was 41.35% per year.

Competitive Comparison of Samsung BioLogics Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Samsung BioLogics Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Samsung BioLogics Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's 3-Year Revenue Growth Rate falls into.


;
;

Samsung BioLogics Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Samsung BioLogics Co  (XKRX:207940) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Samsung BioLogics Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
XKRX:068270 XKRX:196170 XKRX:326030 XKRX:028300 XKRX:214450 XKRX:087010 XKRX:141080 XKRX:145020 XKRX:302440 XKRX:950160 VRTX ASX:CSL REGN ALNY XBRU:UCB XBRU:ARGX ONC BNTX INSM HKSE:01801
Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Website
https://www.samsungbiologics.com
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines